Literature DB >> 4924275

[Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].

A Pletscher, G Bartholini, K F Gey, A Jenni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4924275

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN： 0036-7672


× No keyword cloud information.
  6 in total

1.  Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.

Authors:  A K Granerus; R Jagenburg; A Svanborg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

2.  [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].

Authors:  W Gehlen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974-04-09

3.  L-dopa level in plasma, primary condition for the kinetic effect.

Authors:  W Birkmayer; W Danielcyk; E Neumayer; P Riederer
Journal:  J Neural Transm       Date:  1973       Impact factor: 3.575

4.  [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].

Authors:  E Schneider; P A Fischer; P Jacobi; H Maxion
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1973-03-19

5.  [The therapeutic effect of L-dopa].

Authors:  P Groneberg; A Struppler
Journal:  Naturwissenschaften       Date:  1972-11

6.  Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.

Authors:  T Suzuki; S Higa; S Sakoda; M Ueji; A Hayashi; Y Takaba; A Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.